Singapore, July 21 -- Rege Nephro, a clinical-stage biotechnology startup focused on induced pluripotent stem (iPS) cell-based kidney regenerative medicine and drug discovery, has announced the closing of a financing round totaling approximately $10.6 million through the issuance of J-KISS (Japan-Keep It Simple Security) share acquisition rights.

The proceeds are expected to support commercialisation activities for RN-014, the company's lead candidate for autosomal dominant polycystic kidney disease (ADPKD), advance its iPS cell-derived regenerative medicine program RN-032, and fund continued research and development activities. The financing is intended to support the company's growth through its anticipated Series C financing and beyon...